Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children enrolled in the target schools.~* Written informed consent obtained from the child's parent(s) if they agree to participate.~Exclusion Criteria:~* History of severe hypersensitivity (anaphylactic response) to egg products or previous FluMist~* FluMist is licensed exclusively for use in healthy individuals age 5-49 years. Therefore children for whom annual receipt of inactivated influenza vaccine for specific medical condition(s) is recommended will not be eligible. These conditions include:~* Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart disease, or hemoglobinopathy~* Immunosuppression of child~* Severe immunosuppression of a household member~* Pregnancy~* Past history of Guillian-Barre Syndrome~* Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin containing products for one month after FluMist administration~* Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4 weeks prior to receipt of FluMist~* Received anti-influenza medication in the past 48 hours~* Fever in the past 72 hours~* Moderate to severe nasal congestion (inability to breathe through the nose) or acute phase URI symptoms until the congestion has improved

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): FluMist

Based on this trial design, predict the completion outcome and termination type (if applicable).